CN119836297A - 鼻内施用的用于治疗感觉神经性耳聋的ngf - Google Patents

鼻内施用的用于治疗感觉神经性耳聋的ngf Download PDF

Info

Publication number
CN119836297A
CN119836297A CN202380063408.0A CN202380063408A CN119836297A CN 119836297 A CN119836297 A CN 119836297A CN 202380063408 A CN202380063408 A CN 202380063408A CN 119836297 A CN119836297 A CN 119836297A
Authority
CN
China
Prior art keywords
ngf
concentration
seq
mutant protein
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380063408.0A
Other languages
English (en)
Chinese (zh)
Inventor
瓦妮莎·卡斯特利
安德烈亚·阿拉米尼
劳拉·布兰多利尼
帕斯夸莱·科基亚罗
蒂齐亚纳·罗密欧
尼古拉·代塔
露西娅·阿帕伦特
西蒙娜·马蒂奥利
弗兰卡·卡塔尼
弗拉维奥·曼泰利
马尔塞洛·阿莱格雷蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CN119836297A publication Critical patent/CN119836297A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202380063408.0A 2022-08-05 2023-08-04 鼻内施用的用于治疗感觉神经性耳聋的ngf Pending CN119836297A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22188990.0 2022-08-05
EP22188990.0A EP4316505A1 (en) 2022-08-05 2022-08-05 Intranasal administration of ngf for the treatment of sensorineural hearing loss
PCT/EP2023/071698 WO2024028487A1 (en) 2022-08-05 2023-08-04 Intranasal administration of ngf for the treatment of sensorineural hearing loss

Publications (1)

Publication Number Publication Date
CN119836297A true CN119836297A (zh) 2025-04-15

Family

ID=82846594

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380063408.0A Pending CN119836297A (zh) 2022-08-05 2023-08-04 鼻内施用的用于治疗感觉神经性耳聋的ngf

Country Status (7)

Country Link
EP (2) EP4316505A1 (https=)
JP (1) JP2025525989A (https=)
CN (1) CN119836297A (https=)
AU (1) AU2023317864A1 (https=)
CA (1) CA3263975A1 (https=)
IL (1) IL318657A (https=)
WO (1) WO2024028487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4659759A1 (en) * 2024-06-04 2025-12-10 Dompé farmaceutici SpA Administration of ngf for the treatment of niemann-pick type c disease
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
ITRM20110390A1 (it) * 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
EP2907521B1 (en) 2011-12-19 2017-11-22 Wacker Chemie AG Novel prongf mutants and uses thereof in the production of beta-ngf
WO2017120465A1 (en) * 2016-01-06 2017-07-13 Massachusetts Eye And Ear Infirmary Treating cochlear synaptopathy
US20190374606A1 (en) * 2017-01-27 2019-12-12 Otonomy, Inc. Neurotrophin mutants for treating hearing loss and other otic disorders
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
US12378293B2 (en) 2018-04-27 2025-08-05 Chiesi Farmaceutici Spa Production of nerve growth factor (NGF) and of muteins thereof
TW202229322A (zh) * 2020-11-19 2022-08-01 大陸商舒泰神（北京）生物製藥股份有限公司 長效神經生長因數多肽及其用途

Also Published As

Publication number Publication date
WO2024028487A1 (en) 2024-02-08
IL318657A (en) 2025-03-01
EP4316505A1 (en) 2024-02-07
AU2023317864A1 (en) 2025-02-13
JP2025525989A (ja) 2025-08-07
EP4565255A1 (en) 2025-06-11
CA3263975A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US12102692B2 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
Tonari et al. Blocking endothelin-B receptors rescues retinal ganglion cells from optic nerve injury through suppression of neuroinflammation
CN119836297A (zh) 鼻内施用的用于治疗感觉神经性耳聋的ngf
Aredo et al. Differences in the distribution, phenotype and gene expression of subretinal microglia/macrophages in C57BL/6N (Crb1rd8/rd8) versus C57BL6/J (Crb1wt/wt) mice
US20050095270A1 (en) Drug delivery to the inner ear and methods of using same
US11517554B2 (en) Method for preventing or treating Alzheimer's disease
US20260048006A1 (en) Intranasal administration of bdnf for the treatment of sensorineural hearing loss
CN108310386A (zh) mTOR信号通路抑制剂在制备预防或治疗非遗传性听力障碍药物中的用途
US20240382416A1 (en) Method of treating inflammation and photoreceptor cell degeneration in retinal degeneration patients
CN113855803B (zh) Prmt5抑制剂在用于制备听力保护药物中的用途
US20150374779A1 (en) Pharmacologic treatments of meniére's disease
CN120078740B (zh) 一种基于铁蛋白纳米平台的毛细胞保护剂及其治疗听力损失的应用
EP1547618B1 (en) Drug for auditory dysfunction
US12390510B2 (en) Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
US20240294925A1 (en) Method of Treatment for Auditory Dysfunction
US20240382461A1 (en) Pharmaceutical composition and method for prevention and treatment of hearing loss
US8691765B2 (en) Metallothionein based neuronal therapeutic and therapeutic methods
Tong et al. How Bacterial Vesicles Trigger Hearing Loss: The Role of Pyroptosis in Cochlear Damage
US20110207689A1 (en) The treatment of hearing loss
Xing et al. Pyroptosis Accelerates Spiral Ganglion Neuronal Degeneration Induced by Aminoglycosides in the Cochlea
AU2003233259B2 (en) Metallothionein based neuronal therapeutic and therapeutic methods
Class et al. Patent application title: PHARMACOLOGIC TREATMENTS OF MENIERE'S DISEASE Inventors: Thomas Meyer (Zuchwil, CH)
Kirjavainen et al. silencing the p27" expression, myosin VIla was labeled immuno
HK1262434B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination